Seroprevalence of 10 human papillomavirus types in the general rural population of Anyang, China: A cross-sectional study

Sexually Transmitted Infections

Volumn 91, Issue 7, 2015, Pages 506-509

  Zhang, Chanyuan ^a   Liu, Fangfang ^a   Deng, Qiuju ^a   He, Zhonghu ^a   Xi, Longfu ^b,c   Liu, Ying ^a   Pan, Yaqi ^a   Ning, Tao ^a   Guo, Chuanhai ^a   Xu, Ruiping ^d   Zhang, Lixin ^d   Cai, Hong ^a   Ke, Yang ^a  

^a China   (China)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Anyang Cancer Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; WART VIRUS VACCINE; CAPSID PROTEIN; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CHINA; CHINESE; CROSS-SECTIONAL STUDY; FEMALE; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 3; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 57; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 75; INFECTION RISK; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RURAL POPULATION; SEROLOGY; SEROPREVALENCE; WART VIRUS; YOUNG ADULT; AGE; ALPHAPAPILLOMAVIRUS; BLOOD; CLASSIFICATION; IMMUNOASSAY; IMMUNOLOGY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTOR; SEXUAL BEHAVIOR;

ADULT; AGE FACTORS; ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; RURAL POPULATION; SEROEPIDEMIOLOGIC STUDIES; SEXUAL BEHAVIOR;

EID: 84945535029     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2014-051936     Document Type: Article

References (10)

1. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373:1949-57.
2. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-19.
3. Tiggelaar SM, Lin MJ, Viscidi RP, et al. Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. J Adolesc Health 2012;50:110-31.
4. Zhang C, Liu F, He Z, et al. Seroprevalence of merkel cell polyomavirus in the general rural population of Anyang, China. PLoS ONE 2014;9:e106430.
5. Liu F,Guo F,Zhou Y,et al The Anyang esophageal cancer cohort study: study design, implementation of fieldwork, and use of computer-Aided survey system PLoS ONE 2012 7 e3 1602.
6. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005;51:1845-53.
7. Ji J, Sun HK, Smith JS, et al. Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women. BMC Infect Dis 2012;12:137.
8. Dai M, Bao YP, Li N, et al. Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. Br J Cancer 2006;95:96-101.
9. Thompson DL, Douglas JM Jr, Foster M, et al. Seroepidemiolo gy of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 2004;190:1563-74.
10. Hu Z, Liu H, Li X, et al. HIV-related sexual behaviour among migrants and non-migrants in a rural area of China: role of rural-to-urban migration. Public Health 2006;120:339-45.